Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Down 17.5% in March

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 121,000 shares, a drop of 17.5% from the February 28th total of 146,700 shares. Based on an average daily volume of 322,600 shares, the short-interest ratio is presently 0.4 days. Approximately 0.7% of the company’s stock are short sold.

Institutional Investors Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. National Bank of Canada FI grew its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 45,575 shares of the company’s stock after acquiring an additional 35,575 shares during the quarter. National Bank of Canada FI owned about 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Stock Up 6.1 %

Shares of NASDAQ:SNSE opened at $0.37 on Thursday. The company has a market cap of $9.21 million, a PE ratio of -0.31 and a beta of 0.16. Sensei Biotherapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $1.94. The firm has a 50-day simple moving average of $0.46 and a 200 day simple moving average of $0.49.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its earnings results on Friday, March 28th. The company reported ($0.27) EPS for the quarter, meeting the consensus estimate of ($0.27). As a group, research analysts forecast that Sensei Biotherapeutics will post -1.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SNSE has been the topic of a number of research analyst reports. Oppenheimer increased their target price on Sensei Biotherapeutics from $3.50 to $4.00 and gave the stock an “outperform” rating in a report on Friday, March 28th. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Sensei Biotherapeutics in a research report on Friday, March 28th.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.